Iris Pharma is a leading contract research organization (CRO) dedicated to ophthalmology, helping clients around the world navigate every stage of the drug and medical device development process – including in vivo ocular efficacy studies, Good Laboratory Practice (GLP) preclinical studies, bioanalysis, clinical trials, and marketing surveys. Specializing in offering preclinical and clinical research services worldwide, Iris Pharma has partnered with clients to bring nearly 70 ocular drugs and medical devices to market in the past 26 years. The company offers consulting services to help clients determine the best indication for molecules and products in development. Supporting clients ranging from small start-ups to large pharmaceutical companies and from newcomers to experts in eye therapy, Iris Pharma supports clients in every step of the process, ensuring that the preclinical development program supports the intended clinical trial design and therapeutic use.
Contact
The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of…
Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business…
Carlos Jaime, Head of Samsung’s Health & Medical Equipment Division, France, explains why the future of healthcare is in mobile technology and communications, and how Samsung’s expertise in “digital transformations”…
Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current…
Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake…
Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry…
Eric Le Roy, CEO of the SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The National Association of Medical Technologies Industry), reveals how the French medical devices market is valued at…
Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has…
Jean-Luc Bélingard, chairman of bioMérieux, reveals how the medical community in France has a unique profile, combining both clinical and technological experience, leading to what he describes as the best…
Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device…
Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014:…
While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research.…
See our Cookie Privacy Policy Here
